No material news briefings containing verified events were available for the 30-day period preceding this report's generation date of 2026-09-27. Prior reports on record noted Pfizer's trailing twelve-month revenue figure consistent with the current filing data. The absence of discrete news events in the briefing record means this report relies principally on SEC filing disclosures, institutional holdings records, and prevailing macro data as cited below [Brief - 2026-09-19] [Brief - 2026-09-11].
Pfizer's trailing twelve-month revenue as of 28 June 2026 stood at $63.70 billion, representing year-over-year growth of approximately 2.6%. Net income on a TTM basis was $4.33 billion, with a net margin of 6.80% and an operating margin of 35.19%. The reported P/E ratio was 37.72. EPS on a year-over-year basis contracted by 107.84%, reflecting significant earnings pressure relative to the prior comparable period. Cash on hand was reported at $976 million against total debt of $63.19 billion [SEC 10-Q - PFE - 2026-06-28].
Several notable institutional position changes were recorded in the most recent 13F filings. Citadel added approximately 15% to its existing PFE position [SEC 13F - Citadel - Q2 2026]. AQR Capital increased its holding by approximately 56% [SEC 13F - AQR Capital - Q2 2026]. Millennium added approximately 28% to its position [SEC 13F - Millennium - Q2 2026]. Bridgewater opened a new position in PFE during the same reporting period [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data from SEC Form 4 filings was available in the provided context for this reporting period.
The prevailing macro environment as of the report date shows the 10-year US Treasury yield at 5.18% and the 2-year yield at 4.87%, producing a normal yield curve spread of approximately 31 basis points [FRED DGS10] [FRED DGS2]. These rate levels represent the broader fixed-income context within which Pfizer's $63.19 billion total debt load and its debt servicing costs exist as reported in filings.
This report was generated in response to material institutional position changes across multiple large asset managers, as identified in the most recent round of 13F disclosures. The simultaneous additions by Citadel, AQR Capital, and Millennium, alongside Bridgewater's new position, collectively constitute the primary data event motivating this publication.